Shopping Cart
- Remove All
- Your shopping cart is currently empty
DT-061, an orally bioavailable protein phosphatase 2A (PP2A) activator, may be used in the therapy of KRAS-mutant and MYC-driven tumorigenesis.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,230 | 8-10 weeks | |
50 mg | $1,610 | 8-10 weeks | |
100 mg | $2,440 | 8-10 weeks |
Description | DT-061, an orally bioavailable protein phosphatase 2A (PP2A) activator, may be used in the therapy of KRAS-mutant and MYC-driven tumorigenesis. |
In vivo | DT-061 combined with AZD6244 is more significantly efficient. DT-061 (5 mg/kg, oral gavage, 4 weeks) displays single-agent activity in inhibiting H358 or H441 xenograft growth. |
Molecular Weight | 520.52 |
Formula | C25H23F3N2O5S |
Cas No. | 1809427-19-7 |
Relative Density. | 1.51 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 125 mg/mL (240.14 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.